RCEOP in Diffuse Large B Cell Lymphoma …

Page 1 of 4 WoSCAN CP Ref No.: LYMWOS013/01 Issue Date: August 2009 Review Date: August 2011 West of Scotland Cancer Network Chemotherapy Protocol RCEOP in Diffuse Large B Cell Lymphoma (LYMWOS013/01) Indication First line treatment of Diffuse Large B Cell Lymphoma (includes grade 3b follicular Lymphoma ) in patients not eligible for an anthracycline. Please note: the replacement of doxorubicin with etoposide in this patient group is established local practice in the absence of a definitive reference. Eligibility Inclusion criteria Patients with significant cardiac dysfunction baseline ejection fraction <50%. Patients with borderline cardiac function in the presence of other co-morbidities which may deem them unfit for anthracycline based regimens. Patients who have received or are approaching the maximum cumulative dose of an anthracycline. Treatment Intent Curative Pre-treatment evaluation Informed consent, provision of verbal and written information Assessment of performance status Height, weight and BSA Staging investigations as outlined in CMG If appropriate, discuss the need for contraception in both male and female patients Baseline investigations 1.

First line treatment of Diffuse Large B Cell Lymphoma (includes grade 3b follicular lymphoma) in patients not eligible for an anthracycline. Please note: the replacement of doxorubicin with etoposide in this patient group is established local

Loading..

Tags:

  Large, Cells, Lymphoma, Diffuse large b cell lymphoma, Diffuse

Information

Related search queries